2021-03-19 11:04:12 BYTS Byte Acquisition
03/19/21 03/1911:04 03/19/2111:04 | Byte Acquisition opens at $9.93, IPO priced at $10 per unitByte Acquisition Corporation priced its initial public offering of 30M units at a price of $10.00 per unit and opened at $9.93. The units will be listed on The Nasdaq Capital Market under the ticker symbol "BYTSU." Byte may pursue an acquisition opportunity in any industry or sector, but intends to focus its search for targets in the Israeli technology industry, including those engaged in enterprise software, SaaS, cybersecurity, cloud computing, artificial intelligence and robotics, fintech, automotive technology, semiconductors, medical technology and that offer differentiated technology platforms and products. Each unit issued in the offering consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units commence separate trading, the Class A ordinary shares and warrants are expected to be respectively listed on Nasdaq under the symbols "BYTS" and "BYTSW." Citigroup is acting as sole book-running manager for the offering. |
---|
Downgrade
|
CIFI Holdings downgraded to Neutral from Overweight at JPMorgan »
20:31 08/14/22 08/1420:31 08/14/2220:31
CFFHF
CIFI Holdings
JPMorgan analyst Karl… JPMorgan analyst Karl Chan downgraded CIFI Holdings to Neutral from Overweight with a HK$2.10 price target. |
Upgrade
|
Daiichi Sankyo upgraded to Buy from Hold at Jefferies »
20:30 08/14/22 08/1420:30 08/14/2220:30
DSNKY
Daiichi Sankyo
Jefferies analyst Naoya… Jefferies analyst Naoya Miura upgraded Daiichi Sankyo to Buy from Hold with a 4,300 yen price target. ShowHide Related Items >><<
|
Downgrade
|
Auto Trader Group downgraded to Underweight from Neutral at JPMorgan »
20:28 08/14/22 08/1420:28 08/14/2220:28
ATDRY
Auto Trader Group
JPMorgan analyst Marcus… JPMorgan analyst Marcus Diebel downgraded Auto Trader Group to Underweight from Neutral with a 596 GBp price target. ShowHide Related Items >><<
|
Upgrade
|
Softchoice upgraded to Outperform from Sector Perform at National Bank »
20:26 08/14/22 08/1420:26 08/14/2220:26
SFTC.TO
Softchoice
National Bank analyst… National Bank analyst John Shao upgraded Softchoice to Outperform from Sector Perform with a C$28 price target. ShowHide Related Items >><<
|
Upgrade
|
Plains GP Holdings upgraded to Buy from Hold at Stifel »
20:21 08/14/22 08/1420:21 08/14/2220:21
PAGP
Plains GP Holdings
Plains All American
Stifel analyst Selman… Stifel analyst Selman Akyol upgraded Plains GP Holdings (PAGP) to Buy from Hold with a price target of $16, up from $14. Plains Holdings GP, LP is a tracking stock to Plains All American Pipeline (PAA) and provides investors a 1099 option to gain exposure to PAA's K-1 tax form, noted Akyol, who also upgraded Plains All American to Buy from Hold with a price target of $16 after the company reported Q2 results above his expectations and increased its FY22 EBITDA guidance. ShowHide Related Items >><<
|
Upgrade
|
Plains All American upgraded to Buy from Hold at Stifel »
20:19 08/14/22 08/1420:19 08/14/2220:19
PAA
Plains All American
Stifel analyst Selman… Stifel analyst Selman Akyol upgraded Plains All American to Buy from Hold with a price target of $16, up from $14, after the company reported Q2 results above his expectations and increased its FY22 EBITDA guidance. Plains has utilized a higher commodity price environment to outperform expectations in its NGL segment, said Akyol, who expresses increased confidence in higher volumes and the company's improving balance sheet. ShowHide Related Items >><<
|
Recommendations
|
Seagen price target lowered to $152 from $159 at SVB Securities »
20:14 08/14/22 08/1420:14 08/14/2220:14
SGEN
Seagen
Daiichi Sankyo
Merck
SVB Securities analyst… SVB Securities analyst Andrew Berens lowered the firm's price target on Seagen (SGEN) to $152 from $159 and keeps an Outperform rating on the shares after the company reported that an arbitrator ruled in favor of Daiichi Sankyo (DSNKY) relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate technology. He thinks the decision "comes as a surprise to most investors," but Berens adds that he believes one potential reason that Seagen shares were not down more after announcing the arbitration loss may be that investor speculation increased regarding the reported acquisition discussions being held with Merck (MRK) and the potential that this decision may clear the way for the transaction to occur. ShowHide Related Items >><<
|
Recommendations
|
Pfizer Prevnar-20 miss on co-primary endpoint could help Vaxcyte, says BofA »
20:06 08/14/22 08/1420:06 08/14/2220:06
PCVX
Vaxcyte
Pfizer
BofA analyst Jason… BofA analyst Jason Gerberry noted that Pfizer's (PFE) Prevnar-20 missed on one of the co-primary endpoints in a Phase 3 infant study, which he contends may "introduce some regulatory risk" and open up the market for higher valency vaccines like Vaxcyte's (PCVX). He assumes Pfizer's PCV20 is approved for all indications, but believes higher valency approaches, like VAX-24, still have the potential to be "highly competitive," said Gerberry, who maintains a Buy rating and $37 price target on Vaxcyte shares. ShowHide Related Items >><<
|
Recommendations
|
Futu Holdings price target lowered to $51.50 from $60.60 at BofA »
20:00 08/14/22 08/1420:00 08/14/2220:00
FUTU
Futu Holdings
BofA analyst Emma Xu… BofA analyst Emma Xu lowered the firm's price target on Futu Holdings to $51.50 from $60.60 and keeps a Buy rating on the shares ahead of the company reporting Q2 results before the U.S. market opens on Tuesday, August 30. Futu's earnings and share price have been more correlated historically to the performance of China stocks than U.S. stocks, noted Xu, who We cut 2022-24 earnings estimates by 14%-16% to reflect the market situation. ShowHide Related Items >><<
|
Recommendations
|
MaxCyte price target raised to $11 from $10 at BTIG »
19:54 08/14/22 08/1419:54 08/14/2219:54
MXCT
MaxCyte
BTIG analyst Mark Massaro… BTIG analyst Mark Massaro raised the firm's price target on MaxCyte to $11 from $10 and keeps a Buy rating on the shares following the company's "beat and raise" Q2 report. MaxCyte, unlike other tools companies, is not seeing many industry- headwinds, mainly since a lot of its business is for later-stage product development, Massaro tells investors. ShowHide Related Items >><<
|
Conference/Events
|
PAVmed to host business news update conference call »
16:59 08/14/22 08/1416:59 08/14/2216:59
PAVM
PAVmed
Chairman & CEO Aklog… Chairman & CEO Aklog and CFO McGrath hold a business news update conference call to be held on August 16 at 4:30 pm. Webcast Link ShowHide Related Items >><<
|
Hot Stocks
|
Plus Therapeutics presents data from Ongoing ReSPECT trials »
13:26 08/14/22 08/1413:26 08/14/2213:26
PSTV
Plus Therapeutics
Plus Therapeutics… Plus Therapeutics announced it presented "positive" data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome, or 186RNL, in the treatment of recurrent glioblastoma, or GBM, and leptomeningeal metastases, or LM, at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. The conference, co-sponsored by the Society for Neuro-Oncology and the American Society of Clinical Oncology, is being held August 12-13 in Toronto, Canada. Data show 186RNL treatment is safe and well-tolerated, with no adverse events with outcome of death or discontinuations. At the time of the presentation, four patients remain alive. Cohort 7 of the trial, with an increased dose of 186RNL is currently enrolling. "While we can draw only limited conclusions from the first patient cohort, these findings suggest that the application of locally delivered and highly targeted 186RNL for the treatment of LM has the potential to be an effective and safe treatment for patients," stated Norman LaFrance, M.D., Chief Medical Officer and SVP at Plus Therapeutics. "Taken together, these data from both ReSPECT-LM and ReSPECT-GBM represent Plus' ongoing dedication to evaluating 186RNL in clinical settings and the encouraging results showing our product is safe and effective in treating these difficult-to-treat cancers. As we look ahead to the rest of 2022, we remain focused on completing key manufacturing, clinical and regulatory milestones that will support the further development and validation of 186RNL so we can quickly bring our therapy to patients," added Marc Hedrick, M.D., President and CEO of Plus Therapeutics. ShowHide Related Items >><<
|
Periodicals
|
Affirm CEO says next recession will silence doubters, WSJ reports »
15:08 08/13/22 08/1315:08 08/13/2215:08
AFRM
Affirm
Max Levchin says the… Max Levchin says the market is wrong about Affirm Holdings, the buy now, pay later company he co-founded a decade ago, and it might just take a recession to prove it, The Wall Street Journal's AnnaMaria Andriotis reports. Affirm's stock is down 77% since hitting its peak in November, compared with a 9% decline in the S&P 500 during the same period, as investors worry about future costs of borrowing, growing competition and whether Affirm's borrowers will fall behind on payments during a downturn, the author notes. Levchin is confident that Affirm has safely cracked the code to underwriting more consumers than banks would. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Victoria's Secret is trying a new look, many customers not aware, WSJ reports »
15:05 08/13/22 08/1315:05 08/13/2215:05
VSCO
Victoria's Secret
Victoria's Secret… Victoria's Secret spent the last year trying to shift from a brand associated with the male gaze to a company representing female empowerment, but many customers don't know it made any changes at all, The Wall Street Journal's Khadeeja Safdar reports. Most shoppers who participated in a study conducted by the lingerie seller in February weren't able to identify Victoria's Secret & Co. as the brand behind recent ads of models wearing its lingerie, according to internal research documents reviewed by The Wall Street Journal. The ads show women with different ethnicities, body types and ages mostly in natural-looking lingerie, the author notes. Reference Link ShowHide Related Items >><<
|
Hot Stocks
|
Plus Therapeutics presents data from Oongoing ReSPECT clinical trials »
15:01 08/13/22 08/1315:01 08/13/2215:01
PSTV
Plus Therapeutics
Plus Therapeutics… Plus Therapeutics presented data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome, in the treatment of recurrent glioblastoma and le The oral presentation, titled Safety and Feasibility of Rhenium-186 Nanoliposome in Leptomeningeal Metastases Phase 1/2a Dose Escalation Trial, demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1. Furthermore, all three patients in the cohort were observed to have prompt and complete 186RNL distribution throughout the cerebrospinal fluid subarachnoid space that was durable past one week and very well tolerated. Importantly, all patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92% which was also durable. Another a poster titled, Safety and Feasibility of Rhenium-186 NanoLiposome in Recurrent Glioma: the ReSPECT Phase 1 Trial, demonstrated that in 23 subjects with recurrent GBM receiving a single administration of 186RNL, significant overall survival benefits were observed in those achieving an average absorbed radiation dose greater than 100 Gy to the tumor compared to those with less absorption. These findings suggest a correlation in increasing convected drug volume and radiation dose with improvement in overall survival of patients and to date, 80% of patients in cohorts 5-7 met the threshold of high levels of absorption greater than 100 Gy. Data show 186RNL treatment is safe and well-tolerated, with no adverse events with outcome of death or discontinuations. At the time of the presentation, four patients remain alive. Cohort 7 of the trial, with an increased dose of 186RNL, is currently enrolling. ShowHide Related Items >><<
|
Periodicals
|
Coinbase looking more like a meme stock, Barron's says »
09:48 08/13/22 08/1309:48 08/13/2209:48
COIN
Coinbase
GameStop
AMC Entertainment
Coinbase (COIN) trades… Coinbase (COIN) trades like a side bet on Bitcoin. Lately, though, shares of the crypto brokerage have added meme-stock volatility to the mix, taking cues from the likes of GameStop (GME) and AMC Entertainment (AMC), Joe Light writes in this week's edition of Barron's. Coinbase's volatility arises from several factors. For one, hordes of investors are betting against it. About 18% of Coinbase stock is sold short, the author notes. Such high short interest makes a stock vulnerable to a "squeeze," when traders who had sold borrowed shares - aiming to buy them back later at a lower price - must frantically cover their positions, causing a stock to surge. This helps Coinbase trade untethered from its fundamentals, acting like meme stocks such as AMC and GameStop, both heavily shorted and unmoored from valuation measures like price/earnings ratios, the publication adds. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Best-run auto insurer Progressive may not be best stock to buy, Barron's says »
09:43 08/13/22 08/1309:43 08/13/2209:43
PGR
Progressive
American drivers are back… American drivers are back on the road despite high gas prices, and miles driven are now above pre-pandemic levels. That's bad news for auto insurers, which are reporting some of their worst results in a decade due to elevated claims expenses, Andrew Bary writes in this week's edition of Barron's. Progressive, the No. 3 auto insurer based on premium revenue, continues to distance itself from rivals and take market share, the author notes. But auto insurance costs were up 1.3% in July after rising 1.9% in June, based on the consumer price index. More increases are likely as the industry deals with what Mercury General has termed "extraordinarily high inflation" in claims costs. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Good time to buy stock in Buffet's Berkshire Hathaway, Barron's says »
09:40 08/13/22 08/1309:40 08/13/2209:40
BRK.B
Berkshire Hathaway
Berkshire Hathaway
Berkshire Hathaway has… Berkshire Hathaway has never been in better shape. Its stock looks appealing after pulling back more than 15% from its record high in March, Andrew Bary writes in this week's edition of Barron's. The conglomerate's operating profits were up 22% in the second quarter, excluding foreign-exchange gains, powered by a 56% gain in investment income. Berkshire's annual operating income is running at more than $30 billion after taxes, the author notes. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Royal Caribbean among companies at risk of liquidity squeeze, Barron's says »
09:38 08/13/22 08/1309:38 08/13/2209:38
RCL
Royal Caribbean
Bed Bath & Beyond
Party City
Rite Aid
Wolverine World Wide
Caleres
Express
Rising interest rates and… Rising interest rates and tightening credit conditions could spell trouble for higher-risk issuers that need to refinance debt or borrow more, Evie Lu writes in this week's edition of Barron's. Among those are Royal Caribbean (RCL), Bed Bath & Beyond (BBBY), Party City (PRTY), Rite Aid (RAD), Wolverine World Wide (WWW), Caleres (CAL), and Express (EXPR), the author says. Reference Link ShowHide Related Items >><<
|
Periodicals
|
American Eagle stock set to rise again, Barron's says »
09:28 08/13/22 08/1309:28 08/13/2209:28
AEO
American Eagle
Things admittedly have… Things admittedly have been challenging for American Eagle, Karishma Vanjani writes in this week's edition of Barron's. Still, the stock has believers who say the issues highlighted in the earnings call were temporary and that the company has solutions for the long run. The valuation-at about $2 billion, American Eagle is a small-cap stock-has fallen to a level that likely reflects the worst of the impact, the author adds. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says »
09:14 08/13/22 08/1309:14 08/13/2209:14
LLY
Eli Lilly
Novo Nordisk
New weight-loss drugs,… New weight-loss drugs, known as incretins, from Eli Lilly (LLY) and Novo Nordisk (NVO) have show striking results in studies. If insurers step up to back them, the drugs - and the stocks - could take off, Bill Alpert writes in this week's edition of Barron's. If every hefty American got treated at these drugs' current prices, the annual market for incretins would be a trillion dollars. Insurers can't afford that, of course, and access to the new drugs is highly restricted. But there's plenty of room for prices to come down and still reward Novo and Lilly shareholders, the author notes. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Plug Power, Sunrun among stocks for rush to renewable energy, Barron's says »
09:07 08/13/22 08/1309:07 08/13/2209:07
AES
AES Corp.
Bloom Energy
Freeport-McMoRan
Plug Power
Sunrun
The climate bill in the… The climate bill in the U.S., approved by Congress this past week and sent to President Biden, unlocks $370 billion for clean-energy incentives and consumer benefits, Avi Salzman writes in this week's edition of Barron's. Barron's has identified six promising companies and stocks, including a developer of solar roof projects, two innovators in hydrogen technology, a battery maker, a supplier of green power to utility companies, and a miner of a mineral key to renewables. According to the publication, AES (AES), Bloom Energy (BE), Freeport-McMoRan (FCX), LG Energy Solution, Plug Power (PLUG) and Sunrun (RUN) could make the most of the new opportunities in renewables. Reference Link ShowHide Related Items >><<
|
On The Fly
|
Opening Day: Treasure Global latest to surge following small IPO »
08:56 08/13/22 08/1308:56 08/13/2208:56
HKD
AMTD Digital
Magic Empire Global
Forza X1
Reborn Coffee
Corphousing
Treasure Global
Hainan Manaslu Acquisition
Embrace Change Acquisition
Virax Biolabs
Starbox
GigaCloud
Bitdefender
Amazon.com
Uber
DoorDash
Shares of Malaysian… ShowHide Related Items >><<
|
Conference/Events
|
Hologic participates in a conference call with JPMorgan »
00:28 08/13/22 08/1300:28 08/13/2200:28
HOLX
Hologic
JPMorgan Life Science… JPMorgan Life Science Tools & Diagnostics Analyst Woodring holds a conference call with CEO MacMillan on August 16 at 2 pm hosted by JPMorgan. ShowHide Related Items >><<
|
Conference/Events
|
JPMorgan ai/surface transport analyst to hold analyst/industry conference call »
00:24 08/13/22 08/1300:24 08/13/2200:24
Airfreight & Surface… Airfreight & Surface Transportation Analyst Ossenbeck and European Transports & Logistics Analyst Bland, along with Founder & CEO Schreiber of Freightos, provide an ocean and airfreight update on an Analyst/Industry conference call to be held on August 16 at 10 am. |